208 related articles for article (PubMed ID: 32671329)
1. Highlights of Antibody Engineering and Therapeutics 2019 in San Diego, USA: Bispecific Antibody Design and Clinical Applications.
Zhu Y; Shen R; Hao R; Wang S; Ho M
Antib Ther; 2020 Apr; 3(2):146-154. PubMed ID: 32671329
[TBL] [Abstract][Full Text] [Related]
2. Highlights of 2019 Protein Engineering Summit (PEGS) in Boston, USA: Advancing Antibody-Based Cancer Therapies to the Clinic.
Li H; Li Y; Wang C; Wang S; Ho M
Antib Ther; 2019 Oct; 2(4):79-87. PubMed ID: 31844838
[TBL] [Abstract][Full Text] [Related]
3. Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody.
Moon D; Tae N; Park Y; Lee SW; Kim DH
Immune Netw; 2022 Feb; 22(1):e4. PubMed ID: 35291652
[TBL] [Abstract][Full Text] [Related]
4. Antibody Engineering & Therapeutics, the annual meeting of The Antibody Society December 7-10, 2015, San Diego, CA, USA.
Pauthner M; Yeung J; Ullman C; Bakker J; Wurch T; Reichert JM; Lund-Johansen F; Bradbury AR; Carter PJ; Melis JP
MAbs; 2016; 8(3):617-52. PubMed ID: 26909869
[TBL] [Abstract][Full Text] [Related]
5. A novel brick for bispecific antibody construction.
He Y; Ma H; Wang C; Ai Z; Wu Q; Chen H; Lu D
Proteins; 2023 Aug; 91(8):1065-1076. PubMed ID: 36964928
[TBL] [Abstract][Full Text] [Related]
6. Current landscape and future directions of bispecific antibodies in cancer immunotherapy.
Wei J; Yang Y; Wang G; Liu M
Front Immunol; 2022; 13():1035276. PubMed ID: 36389699
[TBL] [Abstract][Full Text] [Related]
7. Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy.
Zhang T; Lin Y; Gao Q
Cancer Biol Med; 2023 Mar; 20(3):181-95. PubMed ID: 36971124
[TBL] [Abstract][Full Text] [Related]
8. IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA.
Klöhn PC; Wuellner U; Zizlsperger N; Zhou Y; Tavares D; Berger S; Zettlitz KA; Proetzel G; Yong M; Begent RH; Reichert JM
MAbs; 2013; 5(2):178-201. PubMed ID: 23575266
[TBL] [Abstract][Full Text] [Related]
9. Bispecific Antibody Format and the Organization of Immunological Synapses in T Cell-Redirecting Strategies for Cancer Immunotherapy.
Carrasco-Padilla C; Hernaiz-Esteban A; Álvarez-Vallina L; Aguilar-Sopeña O; Roda-Navarro P
Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678761
[TBL] [Abstract][Full Text] [Related]
10. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics.
Li H; Er Saw P; Song E
Cell Mol Immunol; 2020 May; 17(5):451-461. PubMed ID: 32313210
[TBL] [Abstract][Full Text] [Related]
11. Rapid Generation of Murine Bispecific Antibodies Using FAST-Ig
Koga H; Kuroi H; Hirano R; Hirayama H; Nabuchi Y; Kuramochi T
Antibodies (Basel); 2024 Jan; 13(1):. PubMed ID: 38247567
[TBL] [Abstract][Full Text] [Related]
12. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
Fournier P; Schirrmacher V
BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
[TBL] [Abstract][Full Text] [Related]
13. Antibody Engineering & Therapeutics 2016: The Antibody Society's annual meeting, December 11-15, 2016, San Diego, CA.
Larrick JW; Alfenito MR; Scott JK; Parren PW; Burton DR; Bradbury AR; Lemere CA; Messer A; Huston JS; Carter PJ; Veldman T; Chester KA; Schuurman J; Adams GP; Reichert JM
MAbs; 2016; 8(8):1425-1434. PubMed ID: 27557809
[TBL] [Abstract][Full Text] [Related]
14. Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting.
Raje NS; Cohen AD; Patel KK; van de Donk NWCJ; Richter J; San-Miguel J
Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):350-357. PubMed ID: 38627181
[TBL] [Abstract][Full Text] [Related]
15. IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5-8, 2011, San Diego, CA.
Nilvebrant J; Dunlop DC; Sircar A; Wurch T; Falkowska E; Reichert JM; Helguera G; Piccione EC; Brack S; Berger S
MAbs; 2012; 4(2):153-81. PubMed ID: 22453091
[TBL] [Abstract][Full Text] [Related]
16. Biology drives the discovery of bispecific antibodies as innovative therapeutics.
Nie S; Wang Z; Moscoso-Castro M; D'Souza P; Lei C; Xu J; Gu J
Antib Ther; 2020 Jan; 3(1):18-62. PubMed ID: 33928225
[TBL] [Abstract][Full Text] [Related]
17. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies.
Tian Z; Liu M; Zhang Y; Wang X
J Hematol Oncol; 2021 May; 14(1):75. PubMed ID: 33941237
[TBL] [Abstract][Full Text] [Related]
18. "NextGen" Biologics: Bispecific Antibodies and Emerging Clinical Results.
Thakur A; Lum LG
Expert Opin Biol Ther; 2016; 16(5):675-88. PubMed ID: 26848610
[TBL] [Abstract][Full Text] [Related]
19. T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA.
van de Donk NWCJ; O'Neill C; de Ruijter MEM; Verkleij CPM; Zweegman S
Curr Opin Oncol; 2023 Nov; 35(6):601-611. PubMed ID: 37501530
[TBL] [Abstract][Full Text] [Related]
20. Opportunities and challenges of bi-specific antibodies.
Segués A; Huang S; Sijts A; Berraondo P; Zaiss DM
Int Rev Cell Mol Biol; 2022; 369():45-70. PubMed ID: 35777864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
